Where Can You Report Your Adverse Drug Reactions Or Adverse Events Following Immunization

اين يمكنك التبليغ عن الاحداث الجانية للأدوية واللقاحات

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.

How to report

You can send the case reports using the following tools:

For Healthcare Professionals and the Public

The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.

The VigiMobile e-Form and e-Reporting e-Form:

The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones

Scan the QR Code by pressing the link
Click the three dots in the top-right corner
Choose Install app
VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Apple IOS Phones

Scan the QR Code by pressing the link
Click on the share button
Add VigiMobile to the home screen
VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows

Press on the link
Install from the Browser menu
VigiMobile e-Form/e-Reporting e-Form is now installed

Scan QR Codes to Report:

ADRs Following Medication Use	AEFIs Following Vaccine Use

Or use the following link: LNPVP: e-Reporting eForm	Or use the following link: LNPVP: VigiMobile eForm

Direct Contact with the Lebanese National Pharmacovigilance Program:

You may contact the Lebanese National Pharmacovigilance Program through:

Email Address:

pv@moph.gov.lb, pv.moph@gmail.com

Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254

For Market Authorization Holders:

Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.

As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-

...

190

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
N01AH01	FENTANYL PANPHARMA	G	Fentanyl - 0.1mg/2ml	0.1mg/2ml	Injectable solution	1,101,951 L.L
S01EE03	LUMIGAN	B	Bimatoprost - 0.1mg/ml	0.1mg/ml	Drops solution	740,457 L.L
H01CB02	SANDOSTATIN	B	Octreotide - 0.1mg/ml	0.1mg/ml	Injectable solution	1,038,790 L.L
A03BA01	ATROPINE SULFATEAGUETTANT	G	Atropine - 0.1mg/ml	0.1mg/ml	Injectable solution	7,805,376 L.L
C01CA24	ADRENALINE AGUETTANT	G	Adrenaline - 0.1mg/ml	0.1mg/ml	Injectable solution	13,990,891 L.L
S01EE03	LUMIGAN	B	Bimatoprost - 0.1mg/ml	0.1mg/ml	Drops solution	740,457 L.L
C01CA03	NORADRENALINE RENAUDIN	G	Norepinephrine tartrate - 8mg/4ml	0.2%	Injectable solution	2,000,981 L.L
S01EA05	BGLAU	G	Brimonidine tartrate - 0.2%	0.2%	Drops solution	638,325 L.L
S01EA05	BRIMO	G	Brimonidine tartrate - 0.2%	0.2%	Drops solution	658,483 L.L
S01EA05	BRIMONIDINE BIOGARAN	G	Brimonidine tartrate - 2mg/ml	0.2%	Drops solution	412,560 L.L
S01EA05	BRIMOGAN	G	Brimonidine tartrate - 0.2% w/v	0.2% w/v	Drops solution	483,783 L.L
C05AE01	RECTOGESIC	G	Glyceryl trinitrate - 0.2% w/w	0.2% w/w	Ointment	2,553,301 L.L
J01MA02	CIPROX	G	Ciprofloxacine (lactate) - 200mg/100ml	0.2%w/v	Injectable solution	520,067 L.L
D07AC18	PEITEL	B	Prednicarbate - 0.25%	0.25%	Cream	507,972 L.L
D03AX	MEBO	B	?-sitosterol - 0.25%	0.25%	Ointment	760,615 L.L
D03AX	HEALIN B	G	?-sitosterol - 0.25%	0.25%	Ointment	849,820 L.L
D03AX	RENEBO	G	?-sitosterol - 0.25% w/w	0.25% w/w	Ointment	456,906 L.L
A11CC03	ONE-ALPHA	B	Alfacalcidol - 0.25mcg	0.25mcg	Capsule	1,138,235 L.L
L01XK04	TALZENNA	B	Talazoparib - 0.25mg	0.25mg	Capsule	133,836,699 L.L
A10BJ06	OZEMPIC	B	Semaglutide - 0.25mg	0.25mg	Injectable solution	10,927,526 L.L
N05BA12	ALPRAZOLAM BIOGARAN	G	Alprazolam - 0.25mg	0.25mg	Tablet, scored	115,570 L.L
H01CC02	CETROTIDE	B	Cetrorelix (acetate) - 0.25mg	0.25mg	Injectable lyophilised powder for solution+diluent	3,420,079 L.L
H01CC02	CETROTIDE	B	Cetrorelix (acetate) - 0.25mg	0.25mg	Injectable lyophilised powder for solution+diluent	21,354,452 L.L
H01CC02	CETROTIDE	B	Cetrorelix (acetate) - 0.25mg	0.25mg	Injectable lyophilised powder for solution+diluent	21,354,452 L.L
H01CC02	CETROTIDE	B	Cetrorelix (acetate) - 0.25mg	0.25mg	Injectable lyophilised powder for solution+diluent	3,420,079 L.L
L04AA42	MAYZENT	B	Siponimod - 0.25mg	0.25mg	Tablet, film coated	15,102,158 L.L
L04AA42	MAYZENT	B	Siponimod - 0.25mg	0.25mg	Tablet, film coated	124,258,444 L.L
C01AA05	LANOXIN	B	Digoxin - 0.25mg	0.25mg	Tablet	215,015 L.L
H01CC01	ORGALUTRAN	B	Ganirelix - 0.25mg/0.5ml	0.25mg/0.5ml	Injectable solution	2,383,977 L.L
H01CC01	ORGALUTRAN	B	Ganirelix - 0.25mg/0.5ml	0.25mg/0.5ml	Injectable solution	2,383,977 L.L

...

190